vTv Therapeutics (FRA:5VT0) Shiller PE Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
22 GF Score
Price €27.20
View Full Analysis

What is vTv Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


vTv Therapeutics  (FRA:5VT0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


vTv Therapeutics Shiller PE Ratio Related Terms


vTv Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Shiller PE Ratio Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

vTv Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:5VT0 vs BDTX, VANI, TLSA: Shiller PE Ratio Comparison

For the Biotechnology subindustry, vTv Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Shiller PE Ratio falls into.


FRA:5VT0
22GF Score
vTv Therapeutics Inc FRA:5VT0
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

vTv Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, vTv Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.9047/333.9520*333.9520
=-0.905

Current CPI (Jun. 2026) = 333.9520.

vTv Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -14.695 241.428 -20.327
201612 -15.580 241.432 -21.550
201703 -16.513 243.801 -22.619
201706 -14.903 244.955 -20.317
201709 -12.951 246.819 -17.523
201712 -14.948 246.524 -20.249
201803 -9.764 249.554 -13.066
201806 -10.408 251.989 -13.793
201809 -2.224 252.439 -2.943
201812 -3.638 251.233 -4.835
201903 -9.065 254.202 -11.909
201906 -3.659 256.143 -4.771
201909 -4.608 256.759 -5.994
201912 -4.791 256.974 -6.226
202003 -3.946 258.115 -5.106
202006 -2.679 257.797 -3.471
202009 -1.088 260.280 -1.396
202012 0.508 260.474 0.651
202103 -2.494 264.877 -3.144
202106 -0.344 271.696 -0.423
202109 -0.604 274.310 -0.735
202112 -3.695 278.802 -4.426
202203 -3.732 287.504 -4.335
202206 -1.681 296.311 -1.894
202209 -2.102 296.808 -2.365
202212 -2.285 296.797 -2.571
202303 -2.058 301.836 -2.277
202306 -2.535 305.109 -2.774
202309 -3.003 307.789 -3.258
202312 -1.552 306.746 -1.689
202403 -1.082 312.332 -1.157
202406 -0.751 314.175 -0.799
202409 -0.798 315.301 -0.845
202412 -0.518 315.605 -0.548
202503 -0.735 319.799 -0.768
202506 -0.810 322.561 -0.838
202509 -0.924 324.800 -0.950
202512 -0.494 324.054 -0.509
202603 1.410 330.213 1.426
202606 -0.905 333.952 -0.905

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
22GF Score

Get the complete analysis for FRA:5VT0

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.20
Price